| Benlysta (belimumab) / GSK |
ACTRN12607000327482: A Study of Belimumab, a Fully Human Monoclonal Anit-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 3 | 810 | | | Kendle R&D Pty Limited, Human Genome Sciences Inc (HGS) | Systemic Lupus Erythematosus (SLE) | | | | |
2017-003051-35: Efficacy of BELImumab for therapy-resistant SKIN manifestations in patients with lupus erythematosus (LE): A phase III, multicenter, randomized, double-blind, placebo-controlled, 24-week trial (BELI-SKIN) Wirksamkeit von BELImumab bei therapieresistenten Hautmanifestationen bei Patienten mit Lupus erythematodes (LE): Eine Phase III, multizentrische, ran-domisierte, doppel-blinde, Placebo-kontrollierte, 24-wöchige Untersuchung (BELI-SKIN) |
|
|
| Ongoing | 3 | 70 | Europe | Belimumab, AS (GSK1550188), Solution for injection in pre-filled syringe, Belimumab | Rheinische Friedrich-Wilhelms-Universität Bonn, GlaxoSmithKline plc. (GSK) | Patients with lupus erythematosus (LE) with active, therapy-resistant skin manifestations receiving Standard of Care (SOC) therapy Patienten mit Lupus erythematodes (LE) mit aktiven, therapieresistenten Hautmanifestationen unter Standardtherapie, Patients with lupus erythematosus (LE) with active, therapy-resistant skin manifestations receiving Standard of Care (SOC) therapy, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Not yet recruiting | 3 | 132 | Europe | Bélimumab, Solution for injection in pre-filled syringe, BENLYSTA | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), Laboratoire GSK France | Adults with a definite diagnosis of primary chronic immune thrombocytopeniaaccording to the standard definition. Patients with antinuclear antibodies with no definite criteria for systemic lupus will be eligible., adult patients with persistent or chronic immune thrombocytopenia (ITP), Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05262686: Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 10 | RoW | Belimumab, Interleukin-2, Recombinant Human interleukine-2 | Peking University People's Hospital | Systemic Lupus Erythematosus | 06/23 | 06/23 | | |
| Recruiting | 3 | 70 | Europe | Belimumab Injection, Benlysta subcutaneous injection of 200mg | Leiden University Medical Center, Dutch Kidney Foundation, GlaxoSmithKline | Lupus Erythematosus, Systemic | 12/23 | 09/25 | | |
BEAM, NCT05863936: Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis |
|
|
| Recruiting | 3 | 15 | RoW | Methylprednisolone Injectable Suspension, Methylprednisolone pulse therapy, Belimumab Injection, Beliumab induction therapy, Immunosuppressive Agents, Multi-target immunosuppressive therapy | Nanjing University School of Medicine | Lupus Nephritis, Remission, Safety Issues | 03/24 | 12/24 | | |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
RITUX-PLUS 2, NCT05338190: Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 132 | Europe | Combination of Rituximab with subcutaneous belimumab, Combination of Rituximab with subcutaneous placebo | Assistance Publique - Hôpitaux de Paris, GlaxoSmithKline | Primary Immune Thrombocytopenia (ITP) | 11/26 | 11/27 | | |
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 3 | 300 | Europe, Canada, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 02/27 | 02/27 | | |
|
| Recruiting | 2/3 | 15 | Europe | Belimumab | University of Turin, Italy | Antiphospholipid Syndrome | 10/24 | 01/25 | | |
